永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

休市中 11-06 14:46:44

0.375

+0.010

+2.74%

最高0.380	最低0.345	成交量2.16万
今开0.350	昨收0.365	日振幅9.59%
总市值2.32亿	流通市值2.32亿	总股本6.18亿
成交额7,719	换手率0.00%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.375,"timestamp":1793947604071,"preClose":0.365,"halted":0,"volume":21609,"delay":0,"changeRate":0.02739726027397263,"floatShares":618000000,"shares":618000000,"eps":-0.49380354817963645,"marketStatus":"休市中","change":0.01,"latestTime":"11-06 14:46:44","open":0.35,"high":0.38,"low":0.345,"amount":7719,"amplitude":0.09589,"askPrice":0.375,"askSize":5000,"bidPrice":0.345,"bidSize":68000,"shortable":0,"etf":0,"ttmEps":-0.3358981064218601,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.365,"openAndCloseTimeList":[[1793928600000,1793937600000],[1793941200000,1793952000000]],"volumeRatio":0.29201351382920376,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2681849521","title":"进博会观察｜创新药热潮中的支付变局，如何打开商保准入的增量空间？","url":"https://stock-news.laohu8.com/highlight/detail?id=2681849521","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681849521?lang=zh_cn&edition=full","pubTime":"2026-11-08 10:11","pubTimestamp":1794103885,"startTime":"0","endTime":"0","summary":"共识之一是，作为“医药险”闭环中的关键“支付方”，商业保险正成为创新药拓展增量空间的重要领域。进博会期间，武田中国总裁刘燕在主题活动的圆桌论坛中提出。作为重要的支付方，商业保险的推陈出新受到关注。进博会期间，镁信健康升级推出为创新药商保准入打造的AI工作台InsRx.ai。目前，强生创新制药、百时美施贵宝、百济神州、再鼎医药等国内外药企已入驻，已有超过25家药企正在使用InsRx.ai赋能其商保准入布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1794059379023185847","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","IBBQ","LNGR","06978","159992","MEDX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681985172","title":"创新药对外技术授权达1300亿美元！研发重心前移，药械巨头进博会加码本土化","url":"https://stock-news.laohu8.com/highlight/detail?id=2681985172","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681985172?lang=zh_cn&edition=full","pubTime":"2026-11-06 17:18","pubTimestamp":1793956698,"startTime":"0","endTime":"0","summary":"2025年以来，中国创新药行业迎来BD交易大爆发。这一势头在2026年持续，据国家发改委11月3日新闻发布会介绍，今年前三季度，创新药对外技术授权约1300亿美元，已接近去年全年水平。BD交易持续火热的背后，是跨国药企对中国创新药临床研发质量、速度与效率的系统性认可在加速兑现。这种认可并未止步于“买管线”，而是正向跨国药械企业在华本土化布局纵深传导。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611063924900248.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611063924900248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","BK1574","LNGR","MEDX","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681100832","title":"生物制品概念盘中走弱，2026Q3创新药在医药板块内持仓占比降至43%|异动情报","url":"https://stock-news.laohu8.com/highlight/detail?id=2681100832","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681100832?lang=zh_cn&edition=full","pubTime":"2026-11-06 14:50","pubTimestamp":1793947859,"startTime":"0","endTime":"0","summary":"11月6日，生物制品盘中下跌3.04%，相关成分股中，近岸蛋白（688137）下跌12.18%，百普赛斯（301080）下跌11.03%，义翘神州（301047）下跌8.70%，诺唯赞（688105）下跌7.49%，奥浦迈（688293）下跌6.39%。消息面上，2026Q3创新药在医药板块内持仓占比降至43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202611063924769861.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202611063924769861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["159938","MEDX","BK1574","06978","IBBQ","09939","BK1161","159992","LNGR","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681881690","title":"首款CAR-T抗癌新药获批上市！首程控股（0697.HK）投出一家创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2681881690","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681881690?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:11","pubTimestamp":1793923901,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","BK1574","BK1216","00697","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681588974","title":"11月6日每日研选丨创新药迎来业绩兑现期 产业链投资机会持续显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2681588974","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681588974?lang=zh_cn&edition=full","pubTime":"2026-11-06 07:49","pubTimestamp":1793922576,"startTime":"0","endTime":"0","summary":"创新药企业正迎来从“讲故事”到“交成绩单”的关键转变。随着三季报披露收官，一批创新药企业盈利能力明显改善，部分Biotech企业实现扭亏为盈。海外授权交易持续落地，核心产品加速放量，创新药行业正逐步进入业绩收获期。请看机构最新研判。从最新业绩来看，创新药板块基本面持续改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202611063924126754.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202611063924126754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["159992","IBBQ","06978","BK1574","MEDX","LNGR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681855428","title":"欧美药械巨头的“进博宝宝”变了，创新越做越“中国”","url":"https://stock-news.laohu8.com/highlight/detail?id=2681855428","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681855428?lang=zh_cn&edition=full","pubTime":"2026-11-06 06:11","pubTimestamp":1793916662,"startTime":"0","endTime":"0","summary":"每年进博会，晒一晒、比一比各家的“进博宝宝”，已经成为诸多跨国企业的默契。在享有“进博会最卷展区”盛名的医疗器械及医药保健展区，“进博宝宝”——在进博会完成首秀后在中国获批上市的创新药物和医疗器械，其数量和质量更是成了衡量展商综合实力的“硬指标”。进博会进入第九年，越办越好的同时，“进博宝宝”的内涵也在不断升级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611063923955892.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611063923955892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","BK1574","06978","IBBQ","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681005531","title":"股市必读：奥赛康新发布《关于公司创新药奥美妥塔单抗上市许可申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681005531","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681005531?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:55","pubTimestamp":1793901312,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司奥美妥塔单抗注射液的上市许可申请获国家药监局受理，拟用于CLDN18.2阳性晚期胃或胃食管交界处腺癌一线治疗。公司公告汇总关于公司创新药奥美妥塔单抗上市许可申请获得受理的公告北京奥赛康药业股份有限公司子公司江苏奥赛康生物医药有限公司收到国家药品监督管理局出具的《受理通知书》，奥美妥塔单抗注射液的境内生产药品注册上市许可申请获得受理。目前该药处于审评阶段，获批时间与结果存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600002080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK0028","06978","002755","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681077764","title":"A股现积极企稳信号 机构看好AI 产业链与创新药机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2681077764","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681077764?lang=zh_cn&edition=full","pubTime":"2026-11-05 23:35","pubTimestamp":1793892957,"startTime":"0","endTime":"0","summary":"新华财经上海11月5日电（记者魏雨田）近日A股市场止跌回升，三大股指收盘同步录得两连涨，沪深两市成交额连续两个交易日站稳2万亿元，市场呈现“量升价增”的向好信号。国联安基金分析认为，本轮市场大概率已经完成深度调整，筹码基本出清。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/1407,202611053923896061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/1407,202611053923896061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["83188","02846","BK1574","82823","82822","QTOC","159992","82846","BK1610","LNGR","399300","03188","BK1161","02843","ARTY","BK1147","CHAT","MEDX","02827","07233","AIPO","82843","03130","02822","02823","AGIX","VTHR","IBBQ","83130","06978","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681214075","title":"创新药龙头，净利大增超400%！今年3次上调业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2681214075","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681214075?lang=zh_cn&edition=full","pubTime":"2026-11-05 21:20","pubTimestamp":1793884800,"startTime":"0","endTime":"0","summary":"百济神州今年第三次上调业绩预期。 A股总市值4227亿元的百济神州(688235)在披露三季报的同时，再次上调全年业绩预期。百济神州董事长、首席执行官欧雷强表示，这体现了公司全球业务的持续快 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261105/c681523019.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261105/c681523019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1161","IBBQ","MEDX","LNGR","BK1574","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681416970","title":"CRO订单从哪来：创新药BD交易结构升级如何改写研发外包需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2681416970","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681416970?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:23","pubTimestamp":1793866980,"startTime":"0","endTime":"0","summary":"CRO板块的涨停潮把一个问题推到台前：当创新药BD交易从单一管线授权走向平台打包、Co-Co和NewCo，研发外包需求的类型和节奏究竟在发生什么变化？先看交易结构本身。普华永道中国医药医疗行 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261105/c681506147.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261105/c681506147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LNGR","159992","06978","MEDX","IBBQ","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681041611","title":"CRO涨停潮的资金面拆解：公募Q3持仓占比36.9%，21.97倍PE处于七年13%分位","url":"https://stock-news.laohu8.com/highlight/detail?id=2681041611","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681041611?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:23","pubTimestamp":1793866980,"startTime":"0","endTime":"0","summary":"11月4日上午，创新药与CXO方向再度拉升，药明生物、药明康德、百济神州涨幅居前，康龙化成、信达生物、瀚森制药等权重股同步活跃。盘面呈现的并非单一细分赛道的孤立行情，而是从CXO龙头向 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261105/c681506154.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261105/c681506154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["06978","WX","BK1161","LNGR","IBBQ","MEDX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681046292","title":"以岭药业(002603.SZ)：中药创新药“小儿连花感冒颗粒”获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2681046292","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681046292?lang=zh_cn&edition=full","pubTime":"2026-11-05 15:55","pubTimestamp":1793865334,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的中药创新药“小儿连花感冒颗粒”《药品注册证书》。该药品功能主治为：清热解表，宣肺泄热。用于4～12岁儿童风热感冒，症见鼻塞、流浊涕、咽红肿痛、咳嗽、头痛等，舌红，苔薄黄，脉浮数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0097","BK1574","BK0046","159992","IBBQ","BK1161","BK0239","002603","06978","LNGR","MEDX","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681015267","title":"港股异动 | 康哲药业(00867)涨超4% 创新药磷酸芦可替尼乳膏新加坡上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2681015267","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681015267?lang=zh_cn&edition=full","pubTime":"2026-11-05 11:04","pubTimestamp":1793847866,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康哲药业涨超4%，截至发稿，涨4.24%，报10.57港元，成交额1092.92万港元。消息面上，11月4日，康哲药业发布公告，集团附属公司RxilientMedical于2026年11月3日获得新加坡卫生科学局批准磷酸芦可替尼乳膏新药上市许可申请。本次获批，填补了新加坡白癜风治疗领域存在的空白。据悉，康哲药业自2022年起启动“产业国际化”战略，以新加坡为新兴市场业务枢纽，构筑“研、产、销”全产业链高效协同的价值闭环。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999004311.SGD","00867","SG9999015986.USD","BK4588","IE00BGHQDM52.EUR","VXUS","IE00BVYPNP33.GBP","06978","BK4585","IE00BYV24P56.USD","SG9999015945.SGD","IE00BVYPNQ40.USD","BK1161","LU2488822045.USD","STmain","159992","BK1574","SG9999015952.SGD","IE00BMCWC346.EUR","IBBQ","KCAI","SG9999015978.USD","MEDX","LNGR","IPOS","BK1191","BK1593","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681092739","title":"华商基金刘力：科技之外的成长方向中看好创新药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2681092739","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681092739?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:18","pubTimestamp":1793837880,"startTime":"0","endTime":"0","summary":"在科技主线之外，刘力还较为关注被错杀的优质大盘蓝筹标的与成长方向中创新药领域的布局机会。在科技之外的成长方向中，刘力认为，创新药领域长期空间广阔、短期景气度较高，此前也出现了股价与基本面一度背离的情况，相信随着研发兑现与出海突破，优质企业或将迎来价值重估。数据说明：截至2026年09月30日，刘力具有10.2年证券从业经历，其中5.3年证券研究经历、4.9年证券投资经历。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-11-05/doc-inixruna5679999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","BK1161","IBBQ","MEDX","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680037684","title":"奥赛康(002755.SZ)：创新药奥美妥塔单抗上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2680037684","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680037684?lang=zh_cn&edition=full","pubTime":"2026-11-04 19:03","pubTimestamp":1793790224,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥赛康(002755.SZ)发布公告，公司子公司江苏奥赛康生物医药有限公司于近日收到国家药品监督管理局下发的《受理通知书》，公司创新药奥美妥塔单抗的境内生产药品注册上市许可申请获得受理。奥美妥塔单抗注射液，英文通用名为Omectatug;奥美妥塔单抗注射液联合 CAPOX(氟尿嘧啶类和铂类药物)及替雷利珠单抗在用于既往未接受过系统治疗的CLDN18.2阳性、不可切除的局部晚期、复发性或转移性胃及食管胃交界处腺癌患者一线治疗的关键性III期临床试验中，已达到独立评审委员会(IRC)评估的无进展生存期(PFS)主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002755","IPOS","BK1161","06978","BK0239","IBBQ","MEDX","159992","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680038410","title":"信诺维：公司主营业务为创新药物的研究、开发和商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2680038410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680038410?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:18","pubTimestamp":1793780294,"startTime":"0","endTime":"0","summary":"证券之星消息，信诺维11月04日在投资者关系平台上答复投资者关心的问题。公司及下属研发主体是否已设立科技伦理（审查）委员会？公司主营业务为创新药物的研究、开发和商业化，针对抗肿瘤、抗感染等领域开发了多款小分子靶向、复杂抗体及靶向蛋白降解创新药物。公司严格遵守相关法律法规要求，规范开展研发活动。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400029471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680035365","title":"4600亿龙头，尾盘涨停！","url":"https://stock-news.laohu8.com/highlight/detail?id=2680035365","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680035365?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:09","pubTimestamp":1793779746,"startTime":"0","endTime":"0","summary":"A股市场今日午后快速反弹，上证指数收涨2.16%，深证成指涨4.22%，创业板指涨6.4%，科创综指涨9.9%。全市场超4600只个股上涨，成交额20519亿元，较上一交易日增加3368亿元。科技题材午后全线爆发，半导体、存储芯片、CPO、玻璃基板等板块大幅反弹，京仪装备、高凯技术、江丰电子、芯源微等多股“20CM”涨停。成交额前十个股，多数为科技股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1361,202611043921957196.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1361,202611043921957196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["MEDX","UUP","BK1574","06978","IBBQ","UDN","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680080596","title":"港股创新药板块延续涨势，药明康德涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680080596","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680080596?lang=zh_cn&edition=full","pubTime":"2026-11-04 15:28","pubTimestamp":1793777302,"startTime":"0","endTime":"0","summary":"11月4日，港股创新药板块延续涨势，药明康德涨超12%，百济神州涨超10%，康方生物、先声药业等跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611043921927228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611043921927228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2495084118.USD","VXUS","IBBQ","LU1934453819.USD","LU1251922891.USD","IE00B5MMRT66.SGD","06978","LU0455707207.USD","LU2045819591.USD","LU0708995583.HKD","LU1303224171.USD","LU0039217434.USD","LU1770034418.SGD","LU1655091616.SGD","BK1574","LU0572944931.SGD","LU1979443071.USD","LU0700851271.USD","LU0871576103.HKD","LU1997244956.HKD","LU1969619763.USD","LU1481107354.HKD","LU0348766576.USD","LU1719994722.HKD","BK1161","LU2242644610.SGD","LU1046422090.SGD","LU1808992512.USD","LU2328871848.SGD","LU0469268626.HKD","IE00BPRC5H50.USD","LU0501845795.SGD","603259","LNGR","LU0502904849.HKD","BK1141","BK0216","02359","MEDX","LU0320764599.SGD","LU1255011170.USD","LU2488822045.USD","BK4585","KCAI","159992","LU0531971595.HKD","LU2125910500.SGD","LU0149721374.USD","LU0072913022.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680408112","title":"创新药概念持续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2680408112","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680408112?lang=zh_cn&edition=full","pubTime":"2026-11-04 14:15","pubTimestamp":1793772902,"startTime":"0","endTime":"0","summary":"药明康德涨停，此前凯莱英、桂林三金、众生药业涨停，石药创新、百普赛斯、荣昌生物、泰诺麦博等多股涨超10%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611043921858568.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611043921858568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","159992","LNGR","06978","BK1574","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118961689","title":"恒指午后走强涨超1%，创新药概念股强势拉升","url":"https://stock-news.laohu8.com/highlight/detail?id=1118961689","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118961689?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:39","pubTimestamp":1793770784,"startTime":"0","endTime":"0","summary":"11月4日，恒指午后走强涨超1%，创新药概念股强势拉升，$药明生物(02269)$、$药明康德(02359)$涨超9%，$荣昌生物(09995)$、$百济神州(ONC)$涨超8%，$药明合联(02268)$涨超7%，$信达生物(01801)$、$康方生物(09926)$涨超5%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU2328871848.SGD","LU1961090484.USD","LU0128526141.USD","513600","SG9999011746.SGD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU0320764599.SGD","LU0516422440.USD","02833","LU0149721374.USD","LU0128522744.USD","LU1719994722.HKD","LU0072913022.USD","BK1610","07500","LU2125910500.SGD","BK4139","HSImain","LU0359202008.SGD","LU0502904849.HKD","LU2097828557.USD","LU2097828714.EUR","LU2097828805.USD","LU1770034418.SGD","LU1303224171.USD","BK4588","07300","LU2097828474.EUR","BK4526","LU0634319403.HKD","06978","LU0594300419.USD","LU0819121731.USD","LU0856984785.SGD","LU0327786744.USD","LU1251922891.USD","LU0979878070.USD","LU0455707207.USD","IE00BFMHRM44.USD","LU0417516738.SGD","LU2399975544.HKD","02359","LU0359201612.USD","LU0594300179.USD","LU0348735423.USD","LU0348783233.USD","159992","LU0708995153.HKD","LU0823426308.USD","83115","MCHmain","LU0823426480.USD","LU0516423091.SGD","LU0181495838.USD","LU1188198961.HKD","LU0307460666.USD","BK1588","IBBQ","LU2476274308.USD","09926","LU0149534421.HKD","BK1141","LU0456846285.SGD","BK1576","LU0039217434.USD","LU0463099449.HKD","LU0244354667.USD","SG9999014674.SGD","LU0043850808.USD","BK1161","IE00B543WZ88.USD","LU0348784397.USD","LU0348825331.USD","LU0540923850.HKD","LU1242518857.USD","LU0348766576.USD","LU0326950275.SGD","LU2476274720.SGD","LU1831875114.USD","LU2045819591.USD","LU2242644610.SGD","03419","LU3063872942.SGD","MEDX","LU0516422366.SGD","HK0000165453.HKD","BK1574","03037","LU1794554557.SGD","82800","SG9999002463.SGD","SG9999002562.SGD","06160","HHImain","02800","IE00B0JY6N72.USD","LU0708995583.HKD","LU0501845795.SGD","LU0051755006.USD","LU0588546209.SGD","LU0348767384.USD","LU0320764243.SGD","LU2039709279.SGD","LU0417516902.SGD","LU0229945570.USD","BK1583","IE00BPRC5H50.USD","LU0029874905.USD","07200","03115","09995","LU0516423174.USD","LU0456827905.SGD","LU0211977185.USD","LU0348827113.USD","LU0164880469.USD","BK4585","LU2778985437.USD","LU2097828631.EUR","BK1589","LU0828237510.HKD","01801","HSI","BK1500","LU0029874061.USD","LU0052750758.USD","LU0607220059.USD","LU1328277881.USD","LU1969619763.USD","LU0228659784.USD","LU0543330566.HKD","LU1688375341.USD","LU1813983027.USD","09115","LU1720050803.USD","LU0516422952.EUR","LU0572944931.SGD","LU0650527681.SGD","LU1481107354.HKD","LU1242518931.SGD","LU0469268626.HKD","02268","ONC","02269","LU0417516571.SGD","LU1880383366.USD","LU0605514214.HKD","KURE","LU0140636845.USD","LU1046422090.SGD","LU2488822045.USD","LNGR","LU0561508036.HKD","MHImain"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0417},{"period":"1month","weight":-0.0964},{"period":"3month","weight":0.0135},{"period":"6month","weight":-0.569},{"period":"1year","weight":-0.8904},{"period":"ytd","weight":-0.872}],"compareEarnings":[{"period":"1week","weight":0.051},{"period":"1month","weight":0.0146},{"period":"3month","weight":-0.0462},{"period":"6month","weight":-0.0724},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":-0.0448}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.024873},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.014208},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.074202},{"month":11,"riseRate":0.571429,"avgChangeRate":0.007026},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}